Humanized BCMA antibody and BCMA-CAR-T cells
AssigneeCaribou Biosciences, Inc.
InventorsLijun Wu, Vita Golubovskaya
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Claims22
A therapeutic agent for inhibiting growth of BCMA-positive tumors, the agent comprising immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising:
- a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO:
- 5;
- b. a transmembrane domain;
- c. a co-stimulatory domain;
- and
- d. an activating domain;
- and further comprising an excipient.
A method of inhibiting growth of a BCMA-positive tumor, the method comprising administering to a patient having a tumor an effective number of immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising:
- a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO:
- 5;
- b. a transmembrane domain;
- c. a co-stimulatory domain;
- and
- d. an activating domain;
- and further comprising an excipient.
Dependencies are inferred from the claim text.